Hims & Hers is returning to the Super Bowl — one year after its debut spot kicked up a storm of controversy. The telehealth ...

Hims & Hers is quietly building a healthcare platform, aiming to control the primary interface for diagnostics, prevention, and personalized treatments. Learn more.

The jeweler pulled the ads after only five days.

In less than two weeks, more than 120 million people are expected to tune into the biggest advertising moment of the year: ...

Advanced cancer detection, hormone therapies and microdoses of GLP-1 sound like medical treatments for the rich and chic. One company is taking them to the Super Bowl so that anyone can try them.

Last year, Hims & Hers put out a Super Bowl ad—the first for the telehealth giant—that sparked both support and outrage for the way it claimed that Big Pharma prices GLP-1s “ for profits, not patients ...

The telehealth company is back in the fourth quarter of the Big Game, a year after its weight-loss ad drew regulatory and ...

"We fully expect this will ruffle some feathers," Hims & Hers chief design officer, Dan Kenger, told Business Insider.

Hims & Hers is a Strong Buy, as shares appear historically cheap due to temporary margin compression and regulatory concerns. Click here to read more.

A multinational Fortune 500 company which provides a range of engineering services plans to lay off dozens at its Charlottesville-area facility.